Allergios®

Amsterdam, Netherlands All Netherlands companies → — Founded 2020

Point-of-Care Diagnostics Specialty-Focused AI

Allergy & Immunology Laboratory Medicine

Seed (targeting Series A in mid-2026)

Website Claim this company

Products

Allergios®

Lab & Diagnostics

Allergios® is developing an in-vitro diagnostic system that directly visualizes allergic responses in blood serum to provide unambiguous allergy diagnoses, starting with food allergies.

See all 1 product →

About Allergios®

Allergios® is a healthcare AI company focused on revolutionizing allergy diagnostics. The company has developed a method and system, based on research from the University of Bremen and Medical University of Vienna, that directly diagnoses allergies by visualizing the allergic response. Their solution involves an in-vitro allergy diagnostic that analyzes how patient blood serum induces degranulation of basophil cells in the presence of an allergen. This is achieved using a disposable microfluidic chip, an optical reader called GranulEye®, and AI-based analysis software.

The objective of Allergios® is to provide timely and effective treatment options for clinicians by offering a clear and unambiguous allergy diagnosis. The company initially focuses on food allergies, aiming to replace the traditional food challenge test, and plans to expand to other IgE-mediated allergies. Allergios® received a HealthHolland grant in October 2024 to support a public-private partnership with Wageningen University & Research, validating the GranulEye® test for food allergy diagnosis. Following a strategic reset in Q2 2025, Allergios® is currently focused on transforming their technology prototype into a fully validated diagnostic platform, with a Series A funding round targeted for mid-2026.

Focus Areas

allergy diagnostics food allergies in-vitro diagnostics AI-based image analysis microfluidics basophil activation test

Business Intelligence

Technology

cloud-native, AI-based image analysis, disposable microfluidic chip, holography reader (GranulEye®)

What Physicians Need to Know

Specialization in Allergy Diagnostics

Allergiosu00ae specializes in direct allergy diagnostics, focusing on visualizing the allergic response to identify specific allergens. They aim to replace traditional, often risky, allergy testing methods with a cell-based blood test.

Focus on Food Allergies

Initially, Allergiosu00ae is concentrating on food allergies, intending to offer a safer and more effective alternative to the oral food challenge test.

AI-Based Image Analysis

The company leverages AI-based image analysis to interpret the results from their diagnostic system, enhancing the accuracy and reliability of allergy detection.

Microfluidics Technology

Their system incorporates a disposable microfluidic chip, which is a key component in their method for detecting allergies from blood samples.

Basophil Activation Test (BAT)

Allergiosu00ae utilizes a label-free Basophil Activation Test (BAT) to analyze individual immune responses to allergens by visually analyzing basophil degranulation.

In-vitro Diagnostics

The company provides an effective and scalable in-vitro allergy diagnostic solution, which means tests are performed outside the body using blood samples.

Physician Tip

Allergiosu00ae offers a novel approach to allergy diagnosis, particularly for food allergies, by providing a direct, cell-based blood test that aims to be safer and more efficient than current methods like oral provocation tests. The use of a disposable microfluidic chip, an optical reader (GranulEyeu00ae), and AI-based analysis software allows for timely and effective treatment options based on clear and unambiguous diagnoses. This technology can help allergists and immunologists, as well as primary care physicians, to accurately identify causative allergens and monitor the risk of disease onset. The system is designed for integration into routine laboratory workflows and potentially for point-of-care use, minimizing manual intervention. Physicians can anticipate more reliable results due to the use of purified allergens and the ability to detect IgE reactivity towards a broad array of allergens simultaneously with a small serum volume.

Allergiosu00ae is developing a robust, automatable platform for functional, cell-based allergy diagnostics in routine clinical settings. Their system, consisting of a microfluidic chip, a holography reader, and AI-based software, is designed to streamline the diagnostic process. The current focus is on building a reliable, label-free Basophil Activation Test with minimal manual intervention, aiming for integration into routine laboratory workflows and towards point-of-care applications. This suggests a future where their technology could be integrated into existing lab infrastructure for efficient allergy testing.

At a glance

Founded 2020

HQ Amsterdam, Netherlands · Netherlands

CEO Holger Engel

Funding Seed (targeting Series A in mid-2026)

Products 1

Visit site

Products by Allergios®

1 product in the directory

Allergios®

Lab & Diagnostics

Allergios® is developing an in-vitro diagnostic system that directly visualizes allergic responses in blood serum to provide unambiguous allergy diagnoses, starting with food allergies.

Reviews & Opinions

No web reviews on file yet for Allergios®. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Allergios®.

Loading videos...

Videos load interactively. If none appear, search YouTube for Allergios® →

View all on YouTube

Press & Coverage

Allergiosu00ae

Prototype 2.0 in Development – Strategic Update from Allergios

Allergiosu00ae announced a strategic update in August 2025, with Dr. Holger Engel appointed as CEO to lead the development of a robust, automatable GranulEyeu00ae prototype for functional, cell-based allergy diagnostics. The company is focusing on building a reliable, label-free Basophil Activation Test for routine laboratory workflows and potential point-of-care use.

2025-08

Allergiosu00ae

Allergios is awarded HealthHolland grant funding, recognition of the relevance of our innovative IVD test for food allergies

In October 2024, Allergiosu00ae received HealthHolland grant funding for its innovative in-vitro diagnostic (IVD) test for food allergies. This funding supports a public-private partnership with Wageningen University & Research to validate the GranulEyeu00ae test for diagnosing food allergies.

2024-10

AAAAI News Release

Food Allergy Diagnostics are Enhanced by Machine Learning and Deep Learning AI Models

New research presented at the 2026 AAAAI Annual Meeting indicates that machine learning and deep learning AI models significantly improve the diagnostic accuracy of food allergy diagnostics, showing up to a 40% improvement over existing clinical criteria.

2026-02

MDPI

Digital health in allergy care: current practices, evidence, and future prospects

This mini-review from May 2026 summarizes the current applications of digital tools in allergy care, including telemedicine, mobile health technologies, and AI-based decision support systems, highlighting their potential to enhance patient education, symptom monitoring, and personalized diagnostic and therapeutic strategies.

2026-05

PMC

The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases

A January 2025 review article discusses the current progress and future potential of digital health in allergic disease management, focusing on advancements like telehealth, mobile health (mHealth), artificial intelligence, and clinical decision support systems.

2025-01

CBS News

FDA approves first nasal spray for allergic reactions. Here's what to know.

The FDA has approved 'Neffy,' the first needle-free nasal spray for severe allergic reactions, offering an alternative to EpiPens.

unknown

Fox Business

AI-powered app offers personalized allergy forecasts

An AI-powered app, SONUCast, launched in September 2024, provides real-time, personalized allergy symptom forecasts based on a user's location. This app is part of a system that includes the FDA-approved SONU band, a wearable device that uses acoustic vibrational energy for nasal congestion relief.

2024-09

PR Newswire

Children's Hospital Colorado Expands Food Allergy Treatment Options with Launch of Sublingual Immunotherapy Program

Children's Hospital Colorado launched its Sublingual Immunotherapy Program in September 2026, expanding treatment options for children with certain food allergies by helping them build tolerance to up to 10 food allergens through daily liquid drops.

2026-09

Frequently Asked Questions

What specific allergy diagnostic products does Allergiosu00ae offer, and how do they utilize AI-based image analysis and microfluidics?

Allergiosu00ae offers a suite of in-vitro diagnostic products primarily focused on allergy detection. Our core technology leverages microfluidic platforms for efficient sample processing and integrates AI-based image analysis for highly accurate and rapid interpretation of results, particularly in the context of basophil activation tests. This combination aims to provide precise and reproducible diagnostic outcomes for various allergens, including food allergies.

How does Allergiosu00ae address the current concerns and limitations associated with traditional basophil activation tests (BATs)?

Allergiosu00ae addresses common BAT concerns by standardizing the testing process through our microfluidic system, which minimizes variability often seen in manual methods. Our AI-based image analysis enhances the objectivity and reproducibility of results, reducing inter-observer variability and improving the overall reliability and interpretability of the basophil activation test for clinical use.

What is the regulatory compliance status of Allergiosu00ae products, and what evidence supports their clinical validity and utility?

Allergiosu00ae products are developed in accordance with relevant regulatory standards for in-vitro diagnostics. We are actively pursuing necessary certifications and clearances (e.g., FDA, CE Mark) and are conducting clinical studies to generate robust evidence supporting the analytical and clinical validity and utility of our diagnostic platforms in real-world settings.

Can you provide details on the pricing structure for Allergiosu00ae diagnostic solutions and the level of technical support and training offered to healthcare providers?

Our pricing model for Allergiosu00ae diagnostic solutions is designed to be competitive and scalable, with options for various practice sizes and testing volumes. We provide comprehensive technical support, including on-site training for healthcare professionals, ongoing customer service, and readily available resources to ensure seamless integration and optimal use of our platforms.

What are Allergiosu00ae's partnership strategies, and what is the company's long-term stability and vision for the future of allergy diagnostics?

Allergiosu00ae is actively seeking strategic partnerships with leading healthcare institutions, research organizations, and distributors to expand our reach and enhance our product offerings. Our long-term vision is to become a leader in advanced allergy diagnostics, continuously innovating with AI and microfluidics to provide more accurate, accessible, and personalized diagnostic solutions, ensuring sustained company growth and impact.

How does Allergiosu00ae differentiate its food allergy diagnostic capabilities from existing methods on the market?

Allergiosu00ae differentiates its food allergy diagnostics through the integration of AI-based image analysis with microfluidic technology, which allows for highly sensitive and specific detection of allergen-specific basophil activation. This approach aims to provide a more comprehensive and accurate assessment of food allergies compared to traditional methods, potentially reducing false positives and negatives.

What kind of data security and privacy measures are in place for patient information processed through Allergiosu00ae's AI-based systems?

Allergiosu00ae prioritizes data security and patient privacy. Our AI-based systems are designed with robust encryption and anonymization protocols to protect sensitive patient information. We adhere to all relevant data protection regulations (e.g., HIPAA, GDPR) and implement strict access controls to ensure the confidentiality and integrity of all processed data.

Related Companies

Suggest an Edit → | Report an issue